SEC Tracker
Get the app

Nu-Med Plus NUMD

Nu-Med Plus reported a net loss of $56,200 for 2025.

Preliminary proxy statement

Form
PRE 14A
Filed
Importance
Routine
  1. Net loss of $56,200 for the year ended Dec 31, 2025.
  2. Annual meeting to be held virtually on __________, 2026.
  3. Proxy materials available at www.ethigov.com/proxy/numd2026.

Written from the PRE 14A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Nu-Med Plus files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. STRATA Skin Sciences SSKN public float $4M, Jun 30, 2025
  2. ENDRA Life Sciences NDRA public float $3M, Jun 30, 2025
  3. Catheter Precision VJET public float $4M, Jun 30, 2025
  4. Global Innovative Platforms GIPL public float $3M, Sep 30, 2025
  5. Interpace Biosciences IDXG public float $3M, Jun 30, 2025